BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image
Active
Mainboard

Nephrocare Health Services Ltd

Nephrocare Health Services Ltd IPO Details

Listing Date

17 Dec 2025

Bid Price

₹438 - ₹460

Lot Size

32 Shares

Minimum Investment

₹14,720 / Lot

Issue Size

₹871.05 Crores

Employee Discount

₹41 per share

Schedule

    Here are the important dates you need to know in order to participate in this IPO

tick

Bidding starts

10th Dec

tick

Bidding ends

12th Dec

tick

Allotment of shares

15th Dec

tick

Initiation of refund

16th Dec

tick

Credit of shares to Demat account

16th Dec

tick

Listing date

17th Dec

About Nephrocare Health Services Ltd IPO

Incorporated in 2010, Nephrocare Health Services Ltd. operates a network of dialysis clinics offering services such as diagnosis, haemodialysis, home and mobile dialysis, and wellness-focused support backed by an internal pharmacy model. The organisation has expanded its footprint across India and a few international locations through a clinic-based approach to dialysis care. As of 30 September 2025, the network included 519 clinics, with 51 facilities situated in the Philippines, Uzbekistan, and Nepal. In India, Nephrocare was present across 288 cities in 21 States and four Union Territories, with a majority of its centres located in tier II and tier III regions. During FY 2025, the company reported serving 29,281 patients and carrying out 2,885,450 dialysis sessions. It operated 5,562 dialysis machines as of the same date.
 

The company’s operational model includes in-clinic services, mobile dialysis formats, and care pathways that combine treatment and wellness programmes. It also collaborates with multiple hospitals to manage in-house dialysis units, which allows access to patients already receiving care within these facilities. Nephrocare’s service reach reflects a growing shift toward structured dialysis care in areas that have seen limited access historically. The organisation continues to expand its network based on demand for dialysis treatment linked to the rising detection of chronic kidney disease and end-stage renal conditions. As of 30 September 2025, Nephrocare reported having served 31,046 patients and conducted 1,591,377 treatments in India during the six-month period, according to the disclosed operational data.

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 77.29% 66.72%
Public Group 22.71% 33.28%

Nephrocare Health Services Ltd IPO Reservation

QIB Shares Offered 37,71,946 (19.92%)
NII (HNI) Shares Offered 28,28,960 (14.94%)
Retail Shares Offered 66,00,906 (34.86%)
Anchor Investor Shares Offered 56,57,920 (29.88%)
Total Shares Offered 1,89,35,820
Total Shares With Anchor Investor 1,89,35,820

Nephrocare Health Services Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 32 ₹14,720
Retail (Max) 13 416 ₹1,91,360
S HNI (Min) 14 448 ₹2,06,080
S HNI (Max) 67 2,144 ₹9,86,240
B HNI (MIN) 68 2,176 ₹10,00,960

Nephrocare Health Services Ltd IPO Anchor Investor Details

Bid Date December 09, 2025
Shares Offered true
Anchor Investment Details 260.264274

Nephrocare Health Services Ltd IPO registrar

KFin Techologies Ltd
Phone Number +91 40 6716 2222
Email Id nephrocare.ipo@kfintech.com
Website www.kfintech.com

Nephrocare Health Services Ltd IPO Lead Manager

1. ICICI Securities Limited

2. Ambit Private Limited

3. IIFL Capital Services Limited

4. Nomura Financial Advisory & Securities (I) Pvt Ltd

Nephrocare Health Services Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹584.11 cr ₹413.71 cr ₹388.63 cr
Reserves and Surplus ₹582.35 cr ₹411.96 cr ₹383.5 cr
Total Borrowing ₹225.8 cr ₹243.37 cr ₹196.21 cr

Nephrocare Health Services Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
Qualified Institutional Buyers (QIBs) 36,78,793 10,10,69,088 27.4734
Non Institutional Investors (NIIs) 28,86,270 7,00,51,008 24.2704
NII(Bid amount of more than Ten Lakh Rupees) 19,24,180 5,73,66,080 29.8133
NII(Bid amount of more than 2 Lakh < 10 Rupees) 9,62,090 1,26,84,928 13.1848
Retail Individual Investors (RIIs) 67,34,630 1,55,38,304 2.3072
Total 1,33,87,854 18,68,93,536 13.96

Strength of Nephrocare Health Services Ltd

  • India's and Asia's largest dialysis chain with leadership across our markets.
  • Scale coupled with asset-light model driving cost efficiencies and operational excellence.
  • Driving clinical excellence and quality through protocols and advanced technology.
  • Organic growth augmented by proven track record of acquisitions and integration in India and internationally.
  • Patient-centric leadership and seasoned management team backed by marquee investors.
  • Driving sustainable dialysis leadership with environmental, social and governance measures.
  • Track record of sustainable growth, profitability and return.

Risks Involved

  • The company derive a portion of its revenue from operations from the company captive clinics, which are defined as the company dialysis clinics operated within private hospital premises under contractual arrangement, and such captive clinics accounted for 36.51%, 43.30%, 51.96% and 62.23% of its revenue from operations in the six months period ended September 30, 2025 and Fiscals 2025, 2024 and 2023, respectively. If the company contracts for operating captive clinics are cancelled or if its unable to renew or retain similar revenue and operational arrangements, the company business may be materially and adversely affected.
  • The company operate a number of its dialysis clinics under public private partnership ("PPP") contracts awarded by government agencies through a competitive bidding process. Such contracts accounted for 30.96%, 32.62%, 29.24% and 22.39% of the company revenue from operations in the six months period ended September 30, 2025 and Fiscals 2025, 2024 and 2023, respectively. There can be no assurance that the company will qualify for, or that the company will successfully compete and win such tenders, which could have an adverse impact on the company business prospects, results of operations, financial condition and cash flows.
  • Its subject to various operational, reputational, medical and legal risks associated with the operations of the company dialysis services. Failure to establish and comply with appropriate quality standards when performing dialysis services could result in litigation and liability for it and could materially and adversely affect the company reputation and results of operations.
  • The company dependent on healthcare professionals and its business will be impacted significantly if the company unable to attract or retain such professionals.
  • Its may face continuing challenges in further expanding the company operations in cities its currently operate in or in other cities internationally that the company strategically intend to commence operations, which could has an adverse effect on its business prospects and future financial performance.
  • Business interruption at the company dialysis clinics, either standalone, captive or PPP clinics, could result in significant losses and reputational damage to its business.
  • Its subject to operational, reputational, and legal risks associated with the company participation in public private partnership projects. Any failure to perform the company contractual obligations may result in contract termination, blacklisting by public authorities, and exclusion from future government tenders, which could materially and adversely affect its business, results of operations, financial condition and cash flows.
  • Compliance with applicable safety, health and environmental regulations may be costly and adversely affect the company competitive position and results of operations. Regulatory reforms in the healthcare industry in general and associated uncertainty may adversely affect the company business, results of operations and financial condition.
  • The determination of the Price Band is based on various factors and assumptions and the Offer Price, enterprise value to EBITDA, price to earnings ratio and market capitalization to revenue multiple based on the Offer Price of the Company, may not be indicative of the market price of the Company on listing or thereafter.
  • Its subject to risks arising from interest rate and foreign currency exchange rate fluctuations, which could adversely affect the company business, financial condition and results of operations.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Nephrocare Health Services IPO

  • Global dialysis service revenue was assessed at about USD 75.20 billion in 2024, based on market estimates from industry research.

  • The market is projected to expand at an estimated CAGR of 7.1% over the period 2024–2029, reflecting a steady rise in demand for dialysis services.

  • By 2029, the overall market value for dialysis services is estimated to reach around USD 106.2 billion, according to the data cited in the report.

  • This growth outlook is linked to several contributing factors, including the rising incidence of chronic kidney disease (CKD), wider detection of end-stage renal disease (ESRD), and improved availability of dialysis treatment facilities in many regions.

  • The global dialysis patient population is also expected to show a notable increase during the same period.

  • The number of patients undergoing dialysis is projected to rise from approximately 0.28 million in 2024 to about 0.52 million by 2029, reflecting an estimated CAGR of 12.7% for patient growth.


Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Nephrocare Health Services IPO.

 

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
E to E Transportation Infrastructure Limited IPO
Bidding Period
26th Dec 2025 - 12th Dec 2025
Price Range
₹164.0 - 174.0
IPO Size
₹84,22,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amagi Media Labs Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amir Chand Jagadish Kumar Exports Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
APPL Containers Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ardee Engineering Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
PHYTOCHEM REMEDIES INDIA LIMITED IPO
Closing Today
Bidding Period
18th Dec 2025 - 12th Dec 2025
Price Range
₹98.0 - 98.0
IPO Size
₹38,22,00,000
MARC TECHNOCRATS LIMITED IPO
Bidding Period
17th Dec 2025 - 12th Dec 2025
Price Range
₹88.0 - 93.0
IPO Size
₹42,59,00,000
KSH INTERNATIONAL LIMITED IPO
Bidding Period
16th Dec 2025 - 12th Dec 2025
Price Range
₹365.0 - 384.0
IPO Size
₹7,10,00,00,000
NEPTUNE LOGITEK LIMITED IPO
Bidding Period
15th Dec 2025 - 12th Dec 2025
Price Range
₹126.0 - 126.0
IPO Size
₹46,62,00,000
ASHWINI CONTAINER MOVERS LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹135.0 - 142.0
IPO Size
₹71,00,00,000
EXIM ROUTES LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹83.0 - 88.0
IPO Size
₹43,73,00,000
ICICI PRUDENTIAL ASSET MANAGEMENT CO LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹2061.0 - 2165.0
IPO Size
₹1,06,02,65,00,000
STANBIK AGRO LIMITED IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹30.0 - 30.0
IPO Size
₹12,28,00,000
HRS ALUGLAZE LIMITED IPO
Bidding Period
11th Dec 2025 - 12th Dec 2025
Price Range
₹94.0 - 96.0
IPO Size
₹50,92,00,000
PAJSON AGRO INDIA LIMITED IPO
Bidding Period
11th Dec 2025 - 12th Dec 2025
Price Range
₹112.0 - 118.0
IPO Size
₹74,45,00,000
PARK MEDI WORLD LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹154.0 - 162.0
IPO Size
₹9,20,00,00,000
SHIPWAVES ONLINE LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹12.0 - 12.0
IPO Size
₹56,35,00,000
NEPHROCARE HEALTH SERVICES LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹438.0 - 460.0
IPO Size
₹8,71,05,00,000
UNISEM AGRITECH LIMITED IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹63.0 - 65.0
IPO Size
₹21,45,00,000
WAKEFIT INNOVATIONS LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹185.0 - 195.0
IPO Size
₹12,88,89,00,000
K V TOYS INDIA LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹227.0 - 239.0
IPO Size
₹40,15,00,000
RIDDHI DISPLAY EQUIPMENTS LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹95.0 - 100.0
IPO Size
₹24,68,00,000
PRODOCS SOLUTIONS LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹131.0 - 138.0
IPO Size
₹27,60,00,000
CORONA REMEDIES LIMITED IPO
Bidding Period
8th Dec 2025 - 12th Dec 2025
Price Range
₹1008.0 - 1062.0
IPO Size
₹6,55,37,00,000
ENCOMPASS DESIGN INDIA LIMITED IPO
Bidding Period
5th Dec 2025 - 12th Dec 2025
Price Range
₹101.0 - 107.0
IPO Size
₹40,21,00,000
  • All
  • MainBoard
  • SME
ASHWINI CONTAINER MOVERS LIMITED IPO
Issue Prize
142.00
Listing Day Close
140.10(-1.41%)
EXIM ROUTES LIMITED IPO
Issue Prize
88.00
Listing Day Close
115.50(31.82%)
ICICI PRUDENTIAL ASSET MANAGEMENT CO LIMITED IPO
Issue Prize
2165.00
Listing Day Close
2586.70(19.49%)
STANBIK AGRO LIMITED IPO
Issue Prize
30.00
Listing Day Close
33.33(10.00%)
HRS ALUGLAZE LIMITED IPO
Issue Prize
96.00
Listing Day Close
132.30(37.50%)
PAJSON AGRO INDIA LIMITED IPO
Issue Prize
118.00
Listing Day Close
130.20(10.17%)
PARK MEDI WORLD LIMITED IPO
Issue Prize
162.00
Listing Day Close
148.15(-8.64%)
SHIPWAVES ONLINE LIMITED IPO
Issue Prize
12.00
Listing Day Close
11.40(-8.33%)
NEPHROCARE HEALTH SERVICES LIMITED IPO
Issue Prize
460.00
Listing Day Close
471.60(2.61%)
UNISEM AGRITECH LIMITED IPO
Issue Prize
65.00
Listing Day Close
61.75(-4.62%)
WAKEFIT INNOVATIONS LIMITED IPO
Issue Prize
195.00
Listing Day Close
192.30(-1.54%)
K V TOYS INDIA LIMITED IPO
Issue Prize
239.00
Listing Day Close
336.00(40.59%)
RIDDHI DISPLAY EQUIPMENTS LIMITED IPO
Issue Prize
100.00
Listing Day Close
76.00(-24.00%)
PRODOCS SOLUTIONS LIMITED IPO
Issue Prize
138.00
Listing Day Close
151.20(9.42%)
CORONA REMEDIES LIMITED IPO
Issue Prize
1062.00
Listing Day Close
1437.20(35.31%)
ENCOMPASS DESIGN INDIA LIMITED IPO
Issue Prize
107.00
Listing Day Close
193.15(80.37%)
FLYWINGS SIMULATOR TRAINING CENTRE LIMITED IPO
Issue Prize
191.00
Listing Day Close
204.75(7.33%)
METHODHUB SOFTWARE LIMITED IPO
Issue Prize
194.00
Listing Day Close
162.90(-15.98%)
LUXURY TIME LIMITED IPO
Issue Prize
82.00
Listing Day Close
163.59(100.00%)
WESTERN OVERSEAS STUDY ABROAD LIMITED IPO
Issue Prize
56.00
Listing Day Close
52.16(-7.14%)

Frequently Asked Questions

What is Nephrocare Health Services Ltd IPO?

Answer Field

Nephrocare Health Services Ltd IPO is a Mainboard IPO of 1,89,35,820 equity shares of a face value of ₹2 aggregating up to ₹871.05 Crores. The issue is priced at ₹438 to ₹460 per share. The minimum order quantity is 32 Shares. The IPO opens on December 10, 2025, and closes on December 12, 2025. KFin Techologies Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Nephrocare Health Services Ltd IPO will open?

Answer Field

The Nephrocare Health Services Ltd IPO opens on December 10, 2025 and closes on December 12, 2025.

What is the lot size of Nephrocare Health Services Ltd?

Answer Field

Nephrocare Health Services Ltd lot size is 32 shares, and the minimum amount required is ₹14,720.

How to apply for Nephrocare Health Services Ltd IPO?

Answer Field

You can apply in Nephrocare Health Services Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Nephrocare Health Services Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Nephrocare Health Services Ltd IPO will be done on December 15, 2025, and the allotted shares will be credited to your demat account by December 16, 2025.

When is Nephrocare Health Services Ltd IPO listing date?

Answer Field

The Nephrocare Health Services Ltd listing date is December 17, 2025.

Who is the registrar of Nephrocare Health Services Ltd IPO?

Answer Field

The registrar of Nephrocare Health Services Ltd IPO is KFin Techologies Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

ICICI Securities Limited,Ambit Private Limited,IIFL Capital Services Limited,Nomura Financial Advisory & Securities (I) Pvt Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Nephrocare Health Services Ltd IPO?

Answer Field

The fresh issue size is ₹353.41 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Nephrocare Health Services Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 32 shares and ₹14,720 amount.

How can I approve the UPI mandate request for Nephrocare Health Services Ltd IPO?

Answer Field

To apply for Nephrocare Health Services Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Nephrocare Health Services Ltd?

Answer Field

The price of each Nephrocare Health Services Ltd share will be ranging in between ₹438 to ₹460 per share.

What is the cut-off time for the UPI mandate for Nephrocare Health Services Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, December 12, 2025.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|